Dernièrement…

▶️ Retrouvez l’interview de @fabriceplasson pour @LyonDecideurs tournée lors de l’événement Lyon Pôle Bourse le 28 septembre dernier. #biocontrole #news #strategie

📣 Communiqué de Presse : https://bit.ly/3UjM17U
C’est officiel ! Les équipes d’#Amoéba sont heureuses de vous annoncer que l’#US EPA a approuvé l’utilisation du lysat d’amibe Willaertia magna C2c Maky comme #substance active utilisable en #agriculture aux #USA. 🌱

📣 Communiqué de Presse : https://bit.ly/3EWyVc2
🌱 #Amoéba a le plaisir d’annoncer la publication des #résultats d’#essais en champ 2022, une année record en nombre et en performance avec plus de 120 essais réalisés ou en cours à travers le monde

📣 Communiqué de Presse: https://bit.ly/3Th8RwF
💧#Amoéba retire son dossier #biocide au #Canada afin de concentrer nos ressources sur les priorités #stratégiques, telles que le déploiement de notre agent #biocontrôle en Europe et aux USA et du biocide en circuits fermés aux USA

Governance

Executive Committee Members

Fabrice Plasson – Chairman and CEO

Fabrice PLASSON has more than 20 years of experience in the fields of life sciences and biotechnologies.

Before creating Amoéba, he was Managing Director and founder of the French division of DiscoveRx, where he was responsible for sales in Southern Europe. His experience at DiscoveRx gave him a global vision of the sale of products and services to research centers working on the discovery of new drugs.

Fabrice PLASSON previously worked at Whatman Ltd. in France where he was responsible for leading the international distributor network. In this position, he helped Whatman Ltd. to successfully establish itself in the French genetic fingerprinting market. Previously, Fabrice PLASSON had developed Oxoid’s sales and had been called as a consultant on legionella risk by hospitals and companies.

He holds a double master’s degree in Biology and Marketing from the Joseph Fourier University in Grenoble and an Executive MBA (Executive Masters of Business Administration) from EM-Lyon.

Valérie Filiatre – Deputy General Manager

Valérie FILIATRE has acquired more than 30 years of experience in administrative and financial management of European and American listed companies.

Prior to joining Amoéba, Valérie held the position of Chief Financial Officer Europe at ABnote Corporation, one of the world leaders in the security of financial, government, transportation and educational institutions documents. In this position, Valérie was responsible for the consolidation of financial reports for France, Czech Republic, Slovakia and the UK subsidiaries, while contributing to the restructuring of the latter entities.

Valérie is a graduate of EM Lyon, where she specialized in finance and accounting.

Jean-Luc SOUCHE – Business Developer Biocontrol

Jean-Luc SOUCHE, 36 years of experience in life sciences, is a specialist in plant protection. He has held various technical and marketing positions, in France and abroad, at Rhône-Poulenc Agrochimie. After an experience in biotechnology at Metabolic Explorer, he took over the general management of Agrauxine, a French start-up specialized in biocontrol, in 2013, and then assumed the business development after its acquisition by the Lesaffre group. He contributed to the international development of the biofungicide range for vineyards, market gardening and post-harvest treatment of fruits.

Jean-Luc is an Agronomist Engineer from the Institut National Agronomique Paris Grignon (now AgroparisTech) and holds an Executive MBA from HEC.

Sandrine DEMANECHE – Scientific Director

Sandrine DEMANECHE, Doctor of Science, has more than 20 years of experience in research and development in the field of environmental microbiology. She has published 25 articles in peer-reviewed scientific journals. Before joining Amoéba, she was in charge of a sequencing platform and the realization of research projects in microbial ecology in an engineering school (École Centrale de Lyon). Sandrine DEMANECHE is a graduate of the Claude Bernard University in Lyon.

Jean-Baptiste EBERST – Regulatory Affairs Director

Jean-Baptiste EBERST has more than 10 years of experience in Regulatory Affairs in various regulated fields, including healthcare and anti-parasite products. Before joining Amoéba in 2015, he worked in the drug industry (Sanofi Pasteur, Merck Serono) and the medical device industry (Integra LifeSciences), where he was in charge of regulatory management of product portfolios in various areas (USA, Europe, Canada, Middle East). He has a strong background in regulatory product registration and compliance assurance. Jean-Baptiste is a pharmacist, graduated from the University of Strasbourg.

Board of Directors

Amoéba relies on a prestigious and balanced Board of Directors, composed of financiers and industry experts.

 

The speed of Amoeba’s development has always been one of its strengths. Our Board of Directors reflects this need and relies on experts.

Fabrice Plasson – Chairman and CEO

Fabrice Plasson is the CEO and co-founder of Amoéba. He has 20 years of experience in the life sciences and biotechnology industry.

Prior to creating Amoéba, Fabrice Plasson was the CEO and founder of DiscoverX’s French subsidiary and responsible for sales in Southern Europe. DiscoverX is a company specializing in the sale and supply of products and services to research centers to enable them to accelerate the discovery of new drug candidates. Fabrice Plasson was also in charge of the management of international distributors at Whatman Ltd in France. Fabrice Plasson has been a key player in Whatman Ltd allowing it to win the DNA market in France. At the same time, he developed the sales of Oxoid as a consultant to hospitals and industrialists on the risk of legionellosis.

Fabrice Plasson holds a Master’s degree in biology with a specialization in biology and marketing techniques from the Joseph Fourier University in Grenoble. Fabrice Plasson recently graduated with an Executive Masters of Business Administration from EM-Lyon

Valérie Filiatre – Director

Valérie Filiatre is Deputy Managing Director (not a corporate officer) of Amoéba. She has more than 25 years of experience in multinational companies, including 10 years in listed companies.

Prior to joining Amoéba, Valérie Filiatre was CFO Europe of ABnote Group, a leading provider of secure documents for financial, governmental and educational institutions. In charge of the consolidated financial information for the French, Czech, Slovak and British subsidiaries, Valérie Filiatre also actively participated in the restructuring of these entities.

Valérie Filiatre is a graduate of EM-Lyon where she specialized in finance and accounting.

Philippe Dujardin – Director (independent)

Philippe Dujardin has 30 years of experience in growth companies. Previously Deputy CEO of Awabot, CFO of Erytech Pharma, he was also Director of Financing and Investor Relations of Infogrames / Atari Group. He joined BOOSTHEAT in 2014 as Administrative and Financial Director and held the positions of Head of Development of BOOSTHEAT SA (partnerships, offers, international development…) and Director of BOOSTHEAT France.

Philippe Dujardin is a graduate of the Ecole Supérieure de Commerce de Reims and of the Institut d’Etudes Politiques de Lyon.

Bernard Ambolet – Director (independent)

An agricultural engineer, Bernard Ambolet worked for 9 years in a technical institute of applied research (Arvalis-Institut du végétal) and 27 years within the BAYER France group where he carried out various missions as :

– Director of Scientific Affairs,

– Director of Agency,

– Responsible for experimentation and registration of agropharmaceutical specialties for the French market.

In addition to his skills in integrated crop protection, he has a long experience in management and in strategic and systemic approach.

Bernard Ambolet is a full member of the French Academy of Agriculture and a member of the board of the French Association for Plant Protection (AFPP), which has become Vegephyl.

Claudine Vermot-Desroches – Director (independent)

Claudine Vermot-Desroches holds a PhD in molecular biology and immunology from the University of Lyon and is a post-doctoral fellow at the University of Helsinki. She has more than 25 years of experience in the field of biotherapies and has mastered the value chain of a biomedical product, covering the identification of a medical need, the validation of targets, the generation and evaluation of biological drugs, the development of bioprocesses for industrial purposes and the creation of a patent portfolio in immunotherapy.

Claudine Vermot-Desroches has developed 4 drug candidates and also has entrepreneurial experience having co-founded iDD biotech in 2008 and held positions such as Site Manager, R&D Director and member of the Board of Directors.

Claudine Vermot-Desroches currently runs THERAWINGS Consulting – a therapeutic innovation consulting company of which she is the founder.

Ghislaine Pinochet – Director (independent)

Ghislaine Pinochet is an agricultural engineer specialized in Plant Protection. She has a long experience of 38 years in multinational groups (Roussel-Uclaf, Hoechst, Agrevo, Aventis, Bayer, BASF) where she successively held different positions in Development, Business and Marketing, in France and in Europe in the field of Plant Protection and then Seeds.

Since 2010, she has held various positions to establish Bayer’s Seeds business in France and then in Europe and has been, more particularly, in charge of the strategy of innovative projects.

Pascal Reber is a graduate engineer from the Ecole Nationale d’Ingénieurs de Metz and holds a business management degree from Trent Polytechnic in Nottingham.

Pierre Morgon – Censor

Pierre A. MORGON is CEO of MRGN Advisors, Regional Partner for Switzerland at Mérieux Equity Partners and Senior Vice President International Business at CanSino Biologics.
He is Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCB1 and Health Technologies Holding, as well as a non-executive Director of the Boards of Vaccitech and Univercells.

Pierre has over 30 years of experience in the global life sciences industry, particularly in specialty care, vaccines and immunotherapy, leading international operations, in global C-level positions in multinational companies and as CEO of start-up companies.
He is a speaker at several MBA programs and life science conferences, as well as at the Mass Challenge incubator in Switzerland where he also mentors life science startups.

He holds a Ph.D. in pharmacy, an M.B.A. and an MBA. He is also an alumnus of INSEAD and IMD.

Status and internal regulations

Audit Committee

At its meeting of June 22, 2017, the Company’s Board of Directors, using the option provided for in Article R.225-29 of the French Commercial Code, decided to create an Audit Committee from among its members.

Composition of the Audit Committee

As of December 31, 2020, the Audit Committee was composed of two members:

Mr. Pascal Reber, independent director, Chairman of the Audit Committee, and
Mr. Bernard Ambolet, independent director.

Mr. Pascal Reber has particular expertise in financial matters as a result of his professional experience in the finance departments and administrative and supervisory bodies of other companies.

Duties of the Audit Committee

Without prejudice to the powers of the Board of Directors, the Audit Committee is responsible for the tasks referred to in Article L.823-19 of the French Commercial Code.

Operating procedures of the Audit Committee

The rules governing the composition and operation of the Audit Committee have been laid down by the Board of Directors in specific internal regulations, the main terms of which are reproduced below.

The Audit Committee appoints its Chairman from among its members. In the absence of the Chairman, the Audit Committee appoints a Chairman for the meeting. In the event of a tie, the oldest candidate is appointed chairman.

At least half of the members of the Audit Committee must be present at the meeting, or two members if there are only two members.
The members of the Audit Committee may not be represented.

The Audit Committee meets as often as deemed necessary. The Audit Committee is convened by its Chairman, who sets the agenda and sends it to the members of the Audit Committee at least three days before the date of the meeting. Nevertheless, the Audit Committee may meet without delay if circumstances so require.

It may also meet at the request of two of its members or the Chairman of the Board of Directors.

Meetings may be convened by any means, including verbally. Meetings are held at the Company’s registered office or at any other place indicated by the person giving the notice.

The Chairman or the Chairman of the meeting organizes and directs the work of the Audit Committee. He or she ensures that the Audit Committee functions properly and, in particular, that the members of the Audit Committee are able to perform their duties.

The Chairman of the Audit Committee ensures that the Audit Committee’s reports to the Board of Directors enable the Board to be fully informed, thereby facilitating the deliberations of the members of the Board of Directors and their decision-making.